{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:38:54Z","timestamp":1785148734820,"version":"3.55.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Population genomic studies of individuals of Indigenous ancestry have been extremely limited comprising &amp;lt;0.5% of participants in international genetic databases and genome-wide association studies, contributing to a \u201cgenomic gap\u201d that limits their access to personalised medicine. While Indigenous Australians face a high burden of chronic disease and associated medication exposure, corresponding genomic and drug safety datasets are sorely lacking.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> To address this, we conducted a pharmacogenomic study of almost 500 individuals from a founder Indigenous Tiwi population. Whole genome sequencing was performed using short-read Illumina Novaseq6000 technology. We characterised the pharmacogenomics (PGx) landscape of this population by analysing sequencing results and associated pharmacological treatment data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We observed that every individual in the cohort carry at least one actionable genotype and 77% of them carry at least three clinically actionable genotypes across 19 pharmacogenes. Overall, 41% of the Tiwi cohort were predicted to exhibit impaired CYP2D6 metabolism, with this frequency being much higher than that for other global populations. Over half of the population predicted an impaired CYP2C9, CYP2C19, and CYP2B6 metabolism with implications for the processing of commonly used analgesics, statins, anticoagulants, antiretrovirals, antidepressants, and antipsychotics. Moreover, we identified 31 potentially actionable novel variants within Very Important Pharmacogenes (VIPs), five of which were common among the Tiwi. We further detected important clinical implications for the drugs involved with cancer pharmacogenomics such as thiopurines and tamoxifen, immunosuppressants like tacrolimus and certain antivirals used in the hepatitis C treatment due to potential differences in their metabolic processing.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The pharmacogenomic profiles generated in our study demonstrate the utility of pre-emptive PGx testing and have the potential to help guide the development and application of precision therapeutic strategies tailored to Tiwi Indigenous patients. Our research provides valuable insights on pre-emptive PGx testing and the feasibility of its use in ancestrally diverse populations, emphasizing the need for increased diversity and inclusivity in PGx investigations.<\/jats:p>","DOI":"10.3389\/fphar.2023.1180640","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T13:14:26Z","timestamp":1684761266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The pharmacogenomic landscape of an Indigenous Australian population"],"prefix":"10.3389","volume":"14","author":[{"given":"Sumudu Rangika","family":"Samarasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Jadhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"McMorran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivashankar H.","family":"Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"B1","unstructured":"Tiwi Islands 2021 census all persons QuickStats2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cpt.1409","article-title":"Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy","volume":"106","author":"Brown","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.350","article-title":"Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network","volume":"100","author":"Bush","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/17512433.2019.1597706","article-title":"The role of pharmacogenomics in adverse drug reactions","volume":"12","author":"Cacabelos","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: Rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","year":"2015","journal-title":"Gigascience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e105250","DOI":"10.1371\/journal.pone.0105250","article-title":"A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41397-020-00205-5","article-title":"Cyrius: Accurate CYP2D6 genotyping using whole-genome sequencing data","volume":"21","author":"Chen","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B10","unstructured":"Clinical pharmacogenetics implementation consortium2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"Gigascience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/imj.12196","article-title":"Serious statin-associated myotoxicity and rhabdomyolysis in aboriginal and torres strait Islanders: A case series","volume":"43","author":"Gabb","year":"2013","journal-title":"Intern Med. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-007-0445-7","article-title":"The CYP2D6 gene locus in South African coloureds: Unique allele distributions, novel alleles and gene arrangements","volume":"64","author":"Gaedigk","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-genom-083118-015434","article-title":"Genomic research through an indigenous lens: Understanding the expectations","volume":"20","author":"Garrison","year":"2019","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy","volume":"103","author":"Goetz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fphar.2019.01169","article-title":"Variation in actionable pharmacogenetic markers in natives and mestizos from Mexico","volume":"10","author":"Gonzalez-Covarrubias","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-12-369521-5.00013-0","article-title":"Adverse drug reactions","volume-title":"Pharmacology","author":"Hacker","year":"2009"},{"key":"B24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1016416","DOI":"10.3389\/fgene.2022.1016416","article-title":"Allelic diversity of the pharmacogene CYP2D6 in New Zealand M\u0101ori and Pacific peoples","volume":"13","author":"Hitchman","year":"2022","journal-title":"Front. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: A geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/trf.16873","article-title":"The genomic landscape of blood groups in Indigenous Australians in remote communities","volume":"62","author":"Jadhao","year":"2022","journal-title":"Transfusion"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41397-021-00262-4","article-title":"Pharmacogenomic analysis of a genetically distinct Indigenous population","volume":"22","author":"Jaya Shankar","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cpt.2008","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update","volume":"109","author":"Karnes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","unstructured":"Royal Dutch pharmacist's association2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/gim.2016.33","article-title":"Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response","volume":"19","author":"Kozyra","year":"2017","journal-title":"Genet. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00228-013-1581-x","article-title":"Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population","volume":"70","author":"Krishna Kumar","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"","journal-title":"Clin. Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41436-018-0054-0","article-title":"Stargazer: A software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model","volume":"21","author":"Lee","year":"","journal-title":"Genet. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0272129","DOI":"10.1371\/journal.pone.0272129","article-title":"ClinPharmSeq: A targeted sequencing panel for clinical pharmacogenetics implementation","volume":"17","author":"Lee","year":"","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cpt.1552","article-title":"Calling star alleles with stargazer in 28 pharmacogenes with whole genome sequences","volume":"106","author":"Lee","year":"","journal-title":"Clin. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-021-01144-1","article-title":"The extent of medication-related hospital admissions in Australia: A review from 1988 to 2021","volume":"45","author":"Lim","year":"2022","journal-title":"Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2217\/14622416.9.5.511","article-title":"Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature18299","article-title":"A genomic history of Aboriginal Australia","volume":"538","author":"Malaspinas","year":"2016","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cpt.2122","article-title":"Pharmacogenetics at scale: An analysis of the UK Biobank","volume":"109","author":"McInnes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13073-015-0221-8","article-title":"A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases","volume":"7","author":"Miller","year":"2015","journal-title":"Genome Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00702-018-1922-0","article-title":"An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes","volume":"126","author":"Mostafa","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/clpt.2013.203","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-\u03b1-based regimens","volume":"95","author":"Muir","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fgene.2020.00432","article-title":"Analysis of the F2LR3 (PAR4) single nucleotide polymorphism (rs773902) in an indigenous Australian population","volume":"11","author":"Ningtyas","year":"2020","journal-title":"Front. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41467-018-03273-1","article-title":"Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes","volume":"9","author":"Numanagic","year":"2018","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"Bmc Med."},{"key":"B52","unstructured":"PharmGKB [online]2022"},{"key":"B53","unstructured":"Pharmacogene variation consortium [online]2022"},{"key":"B54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"Bmj-British Med. J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31128\/AJGP-10-18-4733","article-title":"Pharmacogenomics in general practice the time has come","volume":"48","author":"Polasek","year":"2019","journal-title":"Aust. J. General Pract."},{"key":"B56","year":"2021"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1371\/journal.pgen.0010070","article-title":"Clines, clusters, and the effect of study design on the inference of human population structure","volume":"1","author":"Rosenberg","year":"2005","journal-title":"PLoS Genet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cts.13153","article-title":"Pharmacogenomic landscape of Indian population using whole genomes","volume":"15","author":"Sahana","year":"2022","journal-title":"Cts-Clinical Transl. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/bcp.14025","article-title":"High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms","volume":"85","author":"Somogyi","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B23","first-page":"577","article-title":"Human Gene Mutation Database (HGMD): 2003 update","volume-title":"Hum Mutat","author":"Stenson","year":"2003"},{"key":"B75","first-page":"942","article-title":"Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank","volume-title":"Nat Genet","author":"Szustakowski","year":"2021"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A review of the important role of CYP2D6 in pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes. (Basel)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fgene.2019.00330","article-title":"New genetic loci associated with chronic kidney disease in an indigenous Australian population","volume":"10","author":"Thomson","year":"2019","journal-title":"Front. Genet."},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5694\/mja15.00937","article-title":"Therapeutic drug safety for indigenous Australians: How do we close the gap?","volume":"204","author":"Thynne","year":"2016","journal-title":"Med. J. Aust."},{"key":"B68","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/cpt.2173","article-title":"StellarPGx: A nextflow pipeline for calling star alleles in cytochrome P450 genes","volume":"110","author":"Twesigomwe","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41525-020-0135-2","article-title":"A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: A focus on CYP2D6 genotyping","volume":"5","author":"Twesigomwe","year":"2020","journal-title":"NPJ Genom Med."},{"key":"B70","volume-title":"U. S. Food and drug administration","year":"2022"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"Annovar: Functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/jmedgenet-2018-105429","article-title":"Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews","volume":"55","author":"Zhou","year":"2018","journal-title":"J. Med. Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00439-021-02385-x","article-title":"Population pharmacogenomics: An update on ethnogeographic differences and opportunities for precision public health","volume":"141","author":"Zhou","year":"2021","journal-title":"Hum. Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T13:14:34Z","timestamp":1684761274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":75,"alternative-id":["10.3389\/fphar.2023.1180640"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1180640","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"article-number":"1180640"}}